ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) CFO Stephen Carey sold 2,850 shares of the firm’s stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $73.00, for a total transaction of $208,050.00. Following the completion of the sale, the chief financial officer owned 168,993 shares in the company, valued at $12,336,489. The trade was a 1.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
ANI Pharmaceuticals Stock Performance
Shares of NASDAQ ANIP traded up $0.10 during midday trading on Wednesday, hitting $72.72. 298,204 shares of the company’s stock were exchanged, compared to its average volume of 384,030. ANI Pharmaceuticals, Inc. has a twelve month low of $69.58 and a twelve month high of $97.00. The firm has a market cap of $1.67 billion, a P/E ratio of 15.67, a PEG ratio of 2.41 and a beta of 0.45. The stock’s 50 day moving average price is $75.50 and its 200-day moving average price is $78.11. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41.
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last posted its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.04 by $0.17. The firm had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm’s revenue was up 25.8% compared to the same quarter last year. During the same period last year, the firm earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.76 EPS for the current year.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on ANIP
Institutional Trading of ANI Pharmaceuticals
Institutional investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company raised its holdings in ANI Pharmaceuticals by 1.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock worth $736,000 after buying an additional 143 shares during the period. Hantz Financial Services Inc. grew its holdings in shares of ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after buying an additional 249 shares in the last quarter. New York State Teachers Retirement System grew its holdings in shares of ANI Pharmaceuticals by 1.6% during the first quarter. New York State Teachers Retirement System now owns 23,268 shares of the specialty pharmaceutical company’s stock valued at $1,789,000 after buying an additional 356 shares in the last quarter. KBC Group NV acquired a new position in ANI Pharmaceuticals during the first quarter valued at $28,000. Finally, Swiss National Bank raised its position in ANI Pharmaceuticals by 1.1% during the first quarter. Swiss National Bank now owns 35,500 shares of the specialty pharmaceutical company’s stock valued at $2,730,000 after buying an additional 400 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.
ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.
Featured Articles
- Five stocks we like better than ANI Pharmaceuticals
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
- O’Reilly Automotive’s Stock Slump Hides a Stronger Business
- McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
- Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
